| Literature DB >> 31711468 |
Annemarie Uhlig1, Johannes Uhlig2,3, Lutz Trojan4, Marc Hinterthaner5, Alexander von Hammerstein-Equord5, Arne Strauss4.
Abstract
BACKGROUND: Multiple surgical treatment options are available for the treatment of ureteropelvic junction obstruction (UPJO). The aim of this study is to compare the most frequently used technics in a comprehensive network approach.Entities:
Keywords: Endoscopy; Laparoscopy; Laparotomy; Minimally invasive surgical procedures; Network meta-analysis
Mesh:
Year: 2019 PMID: 31711468 PMCID: PMC6849262 DOI: 10.1186/s12894-019-0544-7
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Fig. 1Flow diagram of study inclusion process
Study characteristics of included studies
| Author | Publication year | Design | Operative approaches | End points | Study size | Secondary UPJO | Uro-lithiasis | Country | Population | Mean age [years] | Percent female | Follow up [monts] |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baldwin et al. [ | 2003 | retrospective | EP, LP, OP | operative success, operating time, estimated blood loss, transfusion, complications, length of stay, analgesia requirement | 32 | LP 44%, EP 33%, OP 43% | NA | USA | adult | 44,4 and 37 and 42 | NA | 11,0 and 9,9 and 5,4 |
| Bernie et al. [ | 2005 | retrospective | LP, RP | operative success, operating time, estimated blood loss, complications, urinary leakage, length of stay | 14 | NA | NA | USA | adult | 34 and 32 | NA | 24 and 10 |
| Bird et al. [ | 2011 | prospective | LP, RP | operative success, operating time, suturing time, estimated blood loss, conversion, complications, length of stay | 172 | 13% overall | LP 16%, RP 30% | USA | adult | 39,7+/−14,6 | 53 | NA |
| Brooks et al. [ | 1995 | retrospective | EP, LP, OP | operative success, operating time, transfusion, re-operation, complications, length of stay, time to return to normal activity, analgesia requirement | 45 | EP 23%, LP 8%, OP 18% | EP 1%, LP 0%, OP 9% | USA | adult | 42 and 38,4 and 30,6 | 60 | 22,0 and 13,6 and 26,0 |
| Calvert et al. [ | 2008 | retrospective | LP, OP | operative success, operating time, conversion, complications, length of stay | 100 | OP 6%, LP 14% | NA | UK | adult | 36,5 | 77 | 9 and 12 |
| Chen et al. [ | 2016 | retrospective | EP, LP, OP | operative success, operating time, estimated blood loss, conversion, complications, urinary leakage, length of stay | 109 | NA | NA | China | children and adult | 32,8+/−15,6 and 30,9+/− 12,9 and 37,5+/− 12,0 | 39 | 51,9+/− 40,1 |
| Danuser et al. [ | 2012 | NA | LP, RP | operative success, operating time, conversion, complications, length of stay | 82 | NA | NA | Switzerland | NA | NA | NA | NA |
| Desai et al. [ | 2004 | retrospective | EP, LP | operative success, operating time, re-operation, complications, length of stay | 29 | none | NA | USA and India | adult | 38,6+/−16,1 and 38,9+/− 17 | 48 | 31,4+/− 12,6 and 20,0+/−14,0 |
| Fahad [ | 2017 | NA | LP, OP | operative success, operating time, conversion, re-operation, complications, urinary leakage, deaths, length of stay, time to return to normal activity, analgesia requirement | 40 | NA | NA | Iraq | children and adult | 24 | 35 | 9 |
| Garcia-Galisteo et al. [ | 2011 | retrospective | LP, RP | operative success, operating time, suturing time, estimated blood loss, transfusion, complications, deaths, length of stay | 50 | NA | NA | Spain | children and adult | 33,9 | 60 | 20,6 and 42,5 |
| Han et al. [ | 2008 | retrospective | EP, LP | operative success, operating time, transfusion, complications, length of stay, renal function | 45 | EP 31%, LP 13% | NA | Korea | adult | 45,22 and 49,5 ± 13,6 | 47 | 15,2 and 14,3 |
| Hanske et al. [ | 2015 | retrospective | LP, OP | transfusion, re-operation, complications, deaths | 593 | NA | NA | USA | adult | median 48 | 57 | 1 |
| Hemal et al. [ | 2010 | retrospective | LP, RP | operative success, operating time, suturing time, estimated blood loss, conversion, re-operation, complications, length of stay, time to return to normal activity, analgesia requirement | 60 | NA | NA | India | children and adult | 24,9 and 28,1 | 32 | 18 |
| Klingler et al. [ | 2003 | retrospective | LP, OP | operative success, re-operation, complications, pain, analgesia requirement | 55 | LP 8%, OP 0% | NA | Switzerland | adult | 35,9+/−21,1 and 41,0+/−27,9 | 60 | 19,4+/−9,1 and 17,9+/−8,8 |
| Link et al. [ | 2006 | prospective | LP, RP | operating time, complications, urinary leakage | 20 | none | NA | USA | adult | 46,5 and 38,0 | 65 | 5,6 |
| Lucas et al. [ | 2012 | retrospective | LP, RP | operative success, operating time, estimated blood loss, complications, urinary leakage | 759 | RP 27%, LP 24% | RP 18%, LP 12% | North America | NA | 35 | NA | 11+/−13 and 15+/− 16 |
| Memon et al. [ | 2016 | retrospective | LP, OP | operative success, operating time, estimated blood loss, complications, length of stay | 73 | none | NA | Pakistan | adult | 28 and 30 | 59 | 2,7+/−1,2 |
| Mohammed [ | 2017 | prospective | LP, OP | operative success, operating time, estimated blood loss, re-operation, length of stay | 55 | NA | NA | Germany | obese, NA | NA | NA | > 12 |
| Olweny et al. [ | 2012 | retrospective | LP, RP | operative success, operating time, estimated blood loss, conversion, complications, length of stay, analgesia requirement | 20 | none | NA | USA | adult | 40,3 and 35,8 | 57 | 2,8 and 9,2 |
| Pahwa et al. [ | 2014 | pro- and retrospective | LP, OP, RP | operative success, operating time, estimated blood loss, complications, length of stay | 90 | none | NA | India | adult | 31,4 and 34,4 and 32 | 33 | 32,0 and 18,0 and 13,5 |
| Rivas et al. [ | 2015 | retrospective | LP, OP | operative success, conversion, complications, deaths, length of stay | 92 | NA | LP 19%, OP 20% | Spain | adult | 44,5 and 38,5 | NA | 45 |
| Simforoosh et al. [ | 2004 | prospective | LP, OP | operative success, operating time, transfusion, re-operation, complications, urinary leakage, length of stay | 69 | none | NA | Iran | children and adult | 18,2 and 23,1 | 38 | 16,5 and 11,4 |
| Umari et al. [ | 2011 | retrospective | LP, OP | operative success, operating time, conversion, complications, length of stay | 49 | NA | LP 17%, OP 32% | Italy | children and adult | 42 | 51 | 72,3 and 40,9 |
| Wang et al. [ | 2013 | retrospective | LP, OP | operative success, operating time, estimated blood loss, complications, urinary leakage, length of stay, analgesia requirement | 172 | NA | NA | China | children and adult | 21 AND 25 years | 34 | 32,7 AND 38,4 months |
| Weise and Winfield [ | 2006 | prospective | LP, RP | operative success, operating time, estimated blood loss, transfusion, complications, length of stay | 45 | LP 7%, RP 0% | NA | USA | children and adult | 26 and 24,5 | 59 | 6 and 10 |
| Yanke et al. [ | 2008 | retrospective | EP, LP, RP | operative success | 273 | EP 29%; LP 28%, RP 31% | NA | USA | adult | NA | 61 | 20 and 20 and 19 |
Fig. 2Number of comparisons for each end point. a) Comparative studies on success. b) Comparative studies on complications. c) Comparative studies on urinary leakeage. d) Comparative studies on re-operation. e) Comparative studies on transfusion probability. f) Comparative studies on operating time after sensitivity analyses. g) Comparative studies on length of stay
study quality according to the Downs and Black instrument for success and complications
| Baldwin et al. [ | Bernie et al. [ | Bird et al. [ | Brooks et al. [ | Calvert et al. [ | Chen et al. [ | Danuser et al. [ | Desai et al. [ | Fahad [ | Garcia-Galisteo et al. [ | Han et al. [ | Hanske et al. [ | Hemal et al. [ | Klingler et al. [ | Link et al. [ | Lucas et al. [ | Memon et al. [ | Mohammed [ | Olweny et al. [ | Pahwa et al. [ | Rivas et al. [ | Simforoosh et al. [ | Umari et al. [ | Wang et al. [ | Weise and Winfield [ | Yanke et al. [ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Success | ||||||||||||||||||||||||||
| Hypothesis/aim/objective clearly described | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Main outcomes in Introduction or Methods | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | NA | 0 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Patient characteristics clearly described | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | NA | 1 | 1 | NA | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Interventions of interest clearly described | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | NA | 1 | 1 | NA | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Principal confounders clearly described | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 |
| Main findings clearly described | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 0 | 0 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Estimates of random variability provided for main outcomes | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | NA | 1 | 1 | NA | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| All adverse events of intervention reported | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | NA | 1 | 1 | NA | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| Characteristics of patients lost to follow-up described | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Probability values reported for main outcomes | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Subjects asked to participate were representative of source population | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | NA | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Subjects prepared to participate were representative of source population | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | NA | 1 | 1 | NA | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Location and delivery of study treatment was representative of source population | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Study participants blinded to treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blinded outcome assessment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any data dredging clearly described | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Analyses adjust for differing lengths of follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Appropriate statistical tests performed | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | NA | 0 | 0 | NA | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Compliance with interventions was reliable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Outcome measures were reliable and valid | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | NA | 0 | 0 | NA | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| All participants recruited from the same source population | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | NA | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| All participants recruited over the same time period | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | NA | 0 | 1 | NA | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| Participants randomized to treatment(s) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Allocation of treatment concealed from investigators and participants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Adequate adjustment for confounding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Losses to follow-up taken into account | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | NA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Study power | 2 | 1 | 5 | 3 | 4 | 5 | 4 | 2 | 2 | 3 | 3 | NA | 4 | 3 | NA | 5 | 4 | 3 | 2 | 4 | 4 | 4 | 3 | 5 | 3 | 5 |
| Sum | 12 | 6 | 19 | 12 | 13 | 16 | 9 | 9 | 11 | 14 | 14 | NA | 14 | 15 | NA | 23 | 16 | 13 | 15 | 13 | 20 | 13 | 17 | 19 | 17 | 25 |
| Complications | ||||||||||||||||||||||||||
| Hypothesis/aim/objective clearly described | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Main outcomes in Introduction or Methods | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Patient characteristics clearly described | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | NA | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Interventions of interest clearly described | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | NA | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Principal confounders clearly described | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 1 | NA | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 2 |
| Main findings clearly described | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Estimates of random variability provided for main outcomes | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | NA | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| All adverse events of intervention reported | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | NA | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| Characteristics of patients lost to follow-up described | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NA | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Probability values reported for main outcomes | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Subjects asked to participate were representative of source population | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
| Subjects prepared to participate were representative of source population | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Location and delivery of study treatment was representative of source population | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Study participants blinded to treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blinded outcome assessment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any data dredging clearly described | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NA | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Analyses adjust for differing lengths of follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Appropriate statistical tests performed | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | NA | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Compliance with interventions was reliable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Outcome measures were reliable and valid | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | NA | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| All participants recruited from the same source population | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | NA | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| All participants recruited over the same time period | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | NA | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 1 |
| Participants randomized to treatment(s) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Allocation of treatment concealed from investigators and participants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Adequate adjustment for confounding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Losses to follow-up taken into account | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | NA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Study power | 2 | 1 | 5 | 3 | 4 | 5 | 4 | 2 | 2 | 3 | 3 | 5 | 4 | 3 | 1 | 5 | 4 | NA | 2 | 4 | 4 | 4 | 3 | 5 | 3 | 5 |
| Sum | 12 | 6 | 19 | 12 | 13 | 16 | 9 | 9 | 11 | 14 | 14 | 23 | 14 | 15 | 12 | 23 | 16 | NA | 15 | 13 | 20 | 13 | 17 | 19 | 17 | 25 |
NA not applicable
League table showing pairwise comparisons for all surgical approaches and end points included in the quantitative network meta-analysis
| End point | Endopyelotomy (reference) | Laparoscopic pyeloplasty (reference) | Open pyeloplasty (reference) | Robot assisted laparoscopic pyeloplasty (reference) | |
|---|---|---|---|---|---|
| operative success (OR) | EP (comparator) | 1 (1–1), | |||
| LP (comparator) | 1 (1–1), | 0.74 (0.44–1.26), | |||
| OP (comparator) | 1.34 (0.8–2.27), | 1 (1–1), | 0.69 (0.34–1.4), | ||
| RP (comparator) | 1.45 (0.71–2.94), | 1 (1–1), | |||
| EP (reference) | LP (reference) | OP (reference) | RP (reference) | ||
| overall complications (OR) | EP (comparator) | 1 (1–1), | 0.95 (0.41–2.18), | 0.59 (0.25–1.39), | 1.43 (0.54–3.78), |
| LP (comparator) | 1.06 (0.46–2.43), | 1 (1–1), | 1.51 (0.91–2.51), | ||
| OP (comparator) | 1.7 (0.72–4.01), | 1 (1–1), | |||
| RP (comparator) | 0.7 (0.26–1.85), | 0.66 (0.4–1.1), | 1 (1–1), | ||
| EP (reference) | LP (reference) | OP (reference) | RP (reference) | ||
| urinary leakage (OR) | EP (comparator) | 1 (1–1), | 0.14 (0.01–3.01), | 0.17 (0.01–3.41), | 0.25 (0.01–5.95), |
| LP (comparator) | 6.98 (0.33–146.48), | 1 (1–1), | 1.19 (0.39–3.62), | 1.75 (0.74–4.17), | |
| OP (comparator) | 5.87 (0.29–117.38), | 0.84 (0.28–2.56), | 1 (1–1), | 1.47 (0.36–6.05), | |
| RP (comparator) | 3.99 (0.17–94.46), | 0.57 (0.24–1.36), | 0.68 (0.17–2.79), | 1 (1–1), | |
| EP (reference) | LP (reference) | OP (reference) | RP (reference) | ||
| re-operation (OR) | EP (comparator) | 1 (1–1), | 6.18 (0.97–39.29), | 4.75 (0.7–32.39), | 19.18 (0.46–800.12), |
| LP (comparator) | 0.16 (0.03–1.03), | 1 (1–1), | 0.77 (0.32–1.85), | 3.1 (0.12–79.23), | |
| OP (comparator) | 0.21 (0.03–1.43), | 1.3 (0.54–3.14), | 1 (1–1), | 4.04 (0.14–116), | |
| RP (comparator) | 0.05 (0–2.17), | 0.32 (0.01–8.24), | 0.25 (0.01–7.11), | 1 (1–1), | |
| EP (reference) | LP (reference) | OP (reference) | RP (reference) | ||
| transfusion rate (OR) | EP (comparator) | 1 (1–1), | 2.74 (0.33–22.72), | 0.78 (0.07–9.02), | 6.17 (0.14–273.11), |
| LP (comparator) | 0.36 (0.04–3.03), | 1 (1–1), | 0.29 (0.04–2.16), | 2.25 (0.1–52.29), | |
| OP (comparator) | 1.28 (0.11–14.72), | 3.5 (0.46–26.44), | 1 (1–1), | 7.88 (0.19–331.49), | |
| RP (comparator) | 0.16 (0–7.18), | 0.44 (0.02–10.32), | 0.13 (0–5.34), | 1 (1–1), | |
| EP (reference) | LP (reference) | OP (reference) | RP (reference) | ||
| operating time (mean minutes and SD) after sensitivity analyses | EP (comparator) | 0 (0–0), | |||
| LP (comparator) | 0 (0–0), | 12.12 (− 16.84–41.08), | |||
| OP (comparator) | 0 (0–0), | −39.22 (−89.71–11.26), | |||
| RP (comparator) | −12.12 (−41.08–16.84), | 39.22 (− 11.26–89.71), | 0 (0–0), | ||
| EP (reference) | LP (reference) | OP (reference) | RP (reference) | ||
| length of stay (mean days and SD) | EP (comparator) | 0 (0–0), | 0.32 (−2.55–3.18), | −0.69 (−4.76–3.37), | 1.19 (− 2.52–4.9), |
| LP (comparator) | −0.32 (−3.18–2.55), | 0 (0–0), | −1.01 (− 3.89–1.87), | 0.87 (− 1.49–3.23), | |
| OP (comparator) | 0.69 (− 3.37–4.76), | 1.01 (− 1.87–3.89), | 0 (0–0), | 1.88 (− 1.85–5.61), | |
| RP (comparator) | −1.19 (− 4.9–2.52), | −0.87 (− 3.23–1.49), | −1.88 (− 5.61–1.85), | 0 (0–0), | |
Estimates with corresponding statistically significant p-values (p < 0.05) are written in boldface
P-scores ranking the surgical approaches for every outcome based on the amount of certainty that a single treatment outperforms the average of competing interventions. The p-score ranges from 0 to 1, the latter indicating the highest certainty possible
| Endopyelotomy | Laparoscopic pyeloplasty | Open pyeloplasty | Robot assisted laparoscopic pyeloplasty | |
|---|---|---|---|---|
| Operative success | 0.0000 | 0.3797 | 0.6727 | 0.9476 |
| Few overall complications | 0.5583 | 0.4975 | 0.0435 | 0.9007 |
| Few cases of urinary leakage | 0.8584 | 0.1963 | 0.3462 | 0.5991 |
| Low re-operation rate | 0.0476 | 0.6472 | 0.4768 | 0.8284 |
| Low transfusion rate | 0.3089 | 0.6730 | 0.2247 | 0.7934 |
| Short operating time after sensitivity analyses | 0.9958 | 0.0712 | 0.6471 | 0.2860 |
| Short length of stay | 0.4365 | 0.5252 | 0.2589 | 0.7794 |
Fig. 3Pooled estimates for each endpoint. a) operative success. b) complications. c) urinary leakeage. d) re-operation. e) transfusion. f) operating time after sensitivity analyses. g) length of stay